18 F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies

Head Neck. 2019 Feb;41(2):551-561. doi: 10.1002/hed.25513. Epub 2018 Nov 20.

Abstract

Purpose: To evaluate the performance of 18 F-fluorodeoxy-d-glucose positron emission tomography-computed tomography (18 F-FDG PET/CT) in identifying local failure and regional failure following curative radiotherapy or surgery for head and neck squamous cell carcinoma.

Methods: A comprehensive literature search identified studies published between January 2010 and August 2016. Diagnostic performance of 18 F-FDG PET/CT was evaluated for local failure/regional failure stratified by treatment-to-scan time interval of ≤3 versus >3 months.

Results: Twenty-four studies (2627 patients) were included. Compared to ≤3 months, 18 F-FDG PET/CT performed >3 months showed significantly improved sensitivity (87% vs 60%, P = 0.020) and specificity (93% vs 84%, P < 0.001) for local failure. There was no significant difference in sensitivity (79% vs 56%, P = 0.100) or specificity (95% vs 97%, P = 0.35) for regional failure >3 versus ≤3 months.

Conclusions: This meta-analysis confirms high specificity but modest sensitivity of posttreatment 18 F-FDG PET/CT for local failure and regional failure. Sensitivity and specificity are significantly improved when 18 F-FDG PET/CT is performed >3 months for local failure.

Keywords: 18F-FDG PET/CT; head and neck cancer; meta-analysis; molecular imaging; posttreatment surveillance.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / therapy
  • Humans
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals*
  • Sensitivity and Specificity
  • Treatment Failure

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18